Periodontal diseases
Conditions
Interventions
Groups: Control - Sixteen patientes (woman or man) will receive ultrasonic debridemente of the entire mouth in a sigle session, associated with systemic administration of placebo, for 180 days
Test - sixteen patientes (woman or man) will receive ultrasonic debridemente of the entire mouth in a sigle session, associated with systemic administration of resveratrol, for 180 days.
Resveratrol
SRP+RAR Group (1 tooth): Scaling and root planning + photosensitizer Application (10mg / ml methylene blue) + sweep with the tip and laser activation (diode laser 660 nm , 60mw) for 1 minute per sit
SRP Group (1 tooth): Scaling and root planning.
Procedure/surgery
Dietary supplement
G07.203.300.456
Sponsors
Universidade Paulista
Universidade Paulista
Eligibility
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Diagnosis of generalized aggressive periodontitis verified by the presence of true periodontal pockets and radiographic bone loss in patients up to 35 years of age, according to the criteria established by the Academy American Periodontics in 1999; Presence of at least eight teeth with probing depth equal to or above 5 mm (of which two teeth should have probing pocket depth iqual to or above 7 mm) and bleeding on probing; Presence of at least 20 teeth in the oral cavity; Group approaches: Presence of at least two residual periodontal pockets, on posterior teeth without furcation involvement, with probing depth iqual to or above 5 mm and bleeding on probing, three months after non-surgical periodontal treatment.
Exclusion criteria
Exclusion criteria: Periodontal treatment in the 6 months prior to the study; Use of medications, such as antibiotics, anti-inflammatory drugs continuous use, phenytoin, cyclosporine, in the 6 months prior to the study; Presence of systemic changes or active infectious disease (diabetes, heart disease, hepatitis, etc.); Presence of smoking habit; Pregnancy or breastfeeding; Group approaches: Presence of furcation injury; Presence of periapical or pulp changes; Presence of systemic changes or use of medications (6 months prior to the study) that may influence the response to periodontal treatment; Smoking patients; pregnant patients; Patients taking medications such as corticosteroids and antibiotics.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected a gain in clinical attachment level and a reduciton in probing pocket depth in the group treated with resveratrol comparedo to the placebo grop, by means of clinical measurement of clinical attachement level and pocket depth using a periodontal probe. Group approaches: it is expected greater gain in the clinical attachment level and lower pocket depth in the groups receiving photodynamic therapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected reduction in the production of pro-inflammatory factors and increase in the production of anit-inflammatory factors in the group treated with resveratrol compared to the placebo group, through the quantification of inflammatory factors, using the immunoenzimatic assay. | — |
Countries
Brazil
Contacts
Public ContactMônica;Mônica Corrêa;Corrêa
Universidade Paulista;Universidade Paulista
Outcome results
None listed